Froeding, L;
Greimel, E;
Lanceley, A;
Oberguggenberger, A;
Schmalz, C;
Radisic, V;
Nordin, A;
... Jensen, P; + view all
(2018)
Assessing patient-reported quality of life outcomes in vulva cancer patients.
International Journal of Gynecological Cancer
, 28
(4)
pp. 808-817.
10.1097/IGC.0000000000001211.
Preview |
Text
Lanceley_Qol in patients with VC FINAL_IJGC_08012018.pdf - Accepted Version Download (459kB) | Preview |
Abstract
OBJECTIVES: Vulva cancer (VC) treatment carries a high risk of severe late effects that may have a negative impact on quality of life (QoL). Patient-reported outcome measures (PROMs) are increasingly used when evaluating disease- and treatment-specific effects. However, the adequacy of measures used to assess sequelae and QoL in VC remains unclear. The aims of the present study were to evaluate disease- and treatment-related effects as measured by PROMs in VC patients and to identify available VC-specific PROMs. METHODS/MATERIALS: A systematic literature search from 1990 to 2016 was performed. The inclusion criterion was report of disease- and treatment-related effects in VC patients using PROMs in the assessment. Methodological and reporting quality was in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses statement. This systematic review was performed as part of phase 1 of the development of a European Organisation for Research and Treatment of Cancer QoL questionnaire for VC patients. RESULTS: The search revealed 2299 relevant hits, with 11 articles extracted including a total of 535 women with VC; no randomized controlled trials were identified. The selected studies exhibited great heterogeneity in terms of PROMs use. Twenty-one different instruments assessed QoL. Most of the questionnaires were generic. Different issues (sexuality, lymphedema, body image, urinary and bowel function, vulva-specific symptoms) were reported as potentially important, but the results were not systematically collected. Only one VC-specific questionnaire was identified but did not allow for assessment and reporting on a scale level. CONCLUSIONS: Vulva cancer treatment is associated with considerable morbidity deteriorating QoL. To date, there is no validated PROM available that provides adequate coverage of VC-related issues. The study confirms the need for a VC-specific QoL instrument with sensitive scales that allows for broad cross-cultural application for use in clinical trials.
| Type: | Article |
|---|---|
| Title: | Assessing patient-reported quality of life outcomes in vulva cancer patients |
| Open access status: | An open access version is available from UCL Discovery |
| DOI: | 10.1097/IGC.0000000000001211 |
| Publisher version: | http://doi.org/10.1097/IGC.0000000000001211 |
| Language: | English |
| Additional information: | © 2018 by the International Gynecologic Cancer Society and the European Society of Gynaecological Oncology. This version is the author accepted manuscript. For information on re-use, please refer to the publisher’s terms and conditions. |
| UCL classification: | UCL UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Population Health Sciences > UCL EGA Institute for Womens Health UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Population Health Sciences > UCL EGA Institute for Womens Health > Womens Cancer |
| URI: | https://discovery.ucl.ac.uk/id/eprint/10044937 |
Archive Staff Only
 |
View Item |
